Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced fatty acid availability rewires fibroblasts metabolism and decreases collagen deposition in lung fibrosis.

Cellular and molecular life sciences : CMLS·2026
Same author

Outcome of segmentectomy vs. lobectomy in patients with cT1a-b N0 lung cancer and postoperative N1 upstaging.

Langenbeck's archives of surgery·2026
Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Transcriptional landscape of pulmonary artery endothelium reveals subpopulation- and disease-specific remodeling signatures.

Communications biology·2026
Same author

A single-cell atlas revealing cellular heterogeneity across healthy and diseased human thymus.

Nature communications·2026
Same author

MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma.

Diagnostics (Basel, Switzerland)·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K

Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized

Theresa Stork1,2,3, Andreas Ranft3,4, Clemens Aigner1,3,5

  • 1Department of Thoracic Surgery, Ruhrlandklinik, University of Duisburg-Essen, 45239 Essen, Germany.

Cancers
|January 11, 2025
PubMed
Summary
This summary is machine-generated.

Primary mediastinal Ewing sarcoma (EWS) is a rare cancer, accounting for 0.3% of all EWS cases. This study found a 64% five-year survival rate, with surgery improving outcomes for non-metastatic patients.

Keywords:
Ewing sarcomamediastinalmultimodal therapysarcomasoft tissue sarcoma

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.5K

Related Experiment Videos

Last Updated: Jun 3, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.5K

Area of Science:

  • Oncology
  • Pediatric Oncology
  • Sarcoma Research

Background:

  • Primary mediastinal Ewing sarcoma (EWS) is an exceptionally rare malignancy.
  • Few cases have been documented in existing medical literature.
  • Understanding this rare EWS subtype is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the characteristics of primary mediastinal EWS.
  • To analyze patient and treatment data from two international EWS trials.
  • To determine the survival rates and treatment efficacy for this rare cancer.

Main Methods:

  • Retrieved data from the EURO-E.W.I.N.G.99 and EWING 2008 clinical trials.
  • Analyzed patient demographics, diagnostic information, and treatment modalities.
  • Evaluated survival outcomes based on treatment interventions.

Main Results:

  • Primary mediastinal EWS represented 0.3% of all EWS cases (9 out of 2969 patients).
  • The median age at diagnosis was 30.5 years, with 33% presenting with metastases.
  • Five-year survival was 64%; patients undergoing surgery showed favorable survival, with all survivors having had surgery.

Conclusions:

  • Primary mediastinal EWS is exceedingly rare, comprising only 0.3% of EWS cases.
  • The five-year survival rate is comparable to EWS of other origins and favorable compared to other mediastinal sarcomas.
  • Surgical intervention appears to be associated with improved survival in non-metastatic primary mediastinal EWS.